The predictive utility of ABC Score for the antiplatelet effect of clopidogrel in patients with coronary artery disease

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000035690

Enrollment

Unknown

Registered

2020-08-16

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Interventions

Case series:No

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Two thousand consecutive patients with coronary heart disease confirmed by coronary angiography and received coronary intervention, were collected. All of them received 300mg aspirin and 300mg clopidogrel the day before coronary angiography.

Exclusion criteria

Exclusion criteria: 1. Taking cilostazol, tirofiban, or ticagrelor at the same time; 2. Taking oral anticoagulation drugs such as warfarin at the same time; 3. Contraindications to the use of aspirin or clopidogrel; 4. Serious complications (coronary dissection, pericardial tamponade, cardiogenic shock, ventricular fibrillation, etc.) occurred during coronary intervention. 5. Platelets less than 100 x 10^9/L; 6. Patients with hematologic disease or high risk of bleeding; 7. Patients with malignant tumor; 8. Pregnant women; 9. Patients with severe renal insufficiency; 10. Patients with impaired liver function.

Design outcomes

Primary

Measure	Time frame
high residual platelet reactivity, HRPR;	—

Secondary

Measure	Time frame
peri-procedure myocardial injury, PMI;	—

Countries

China

Contacts

Public ContactWu Hongyi

Zhongshan Hospital, Fudan University

wu.hongyi@zs-hospital.sh.cn+86 13817165522

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026